Patents Assigned to Molecular Innovations, Inc.
  • Patent number: 9085795
    Abstract: The present invention relates to antibodies that bind to prorenin. In particular, the invention relates to monoclonal antibodies that bind to prorenin and inhibit the activation of prorenin. The antibodies of the invention are useful for screening for candidate agents that inhibit the activation of prorenin and candidate agents the modulate the activity of renin. The antibodies are also useful as diagnostics and for treating disease states.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: July 21, 2015
    Assignee: MOLECULAR INNOVATIONS, INC.
    Inventor: Duane E. Day
  • Patent number: 7015021
    Abstract: The present disclosure relates to a single step method for purifying PAI-1, PAI-1 fragments and PAI-1 mutants using a metal chelate resin. The disclosure further relates to the purified PAI-1 obtained by the disclosed method and uses for the purified PAI-1.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: March 21, 2006
    Assignee: Molecular Innovations, Inc.
    Inventor: Duane D. Day
  • Publication number: 20050244893
    Abstract: The invention provides a novel assay system for measuring the amount of active PAI-1 in a sample with sensitivity, and correlation to an active PAI-1 amount. The assay determines the amount of active PAI-1 in a sample by utilizing a novel standard curve. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. 37 CFR 1.72(b).
    Type: Application
    Filed: April 15, 2005
    Publication date: November 3, 2005
    Applicants: Wyeth, Molecular Innovations, Inc.
    Inventors: David Crandall, Duane Day
  • Patent number: 6063568
    Abstract: A method for the quantitative monitoring of gene expression without either co-amplification of an added template or use of an endogenous constitutive transcript is provided. The process involves a duplex amplification reaction in which a single set of primers is used to amplify both genomic DNA and expressed mRNA from the same gene sequence. These primers are targeted for sequences flanking the splice junction/intron sequences for the mRNA/DNA respectively. By their use, any suitable nucleic acid amplification technology yields mRNA and DNA amplimers which are distinguishable by length and sequence heterogeneity. These amplimers are present in the final amplification reaction in ratios which are dependent upon the ratios of the expressed mRNA to the DNA in the sample, allowing the quantitation of mRNA in a sample which is normalized to the number of copies of genomic DNA since the genomic DNA acts as the internal quantitation standard, and in effect yields the amount of mRNA per cell.
    Type: Grant
    Filed: May 2, 1997
    Date of Patent: May 16, 2000
    Assignee: Molecular Innovations, Inc.
    Inventors: John C. Gerdes, Jeffrey M. Marmaro
  • Patent number: 5989813
    Abstract: The invention describes an assay for detecting amplified target nucleic acid sequences with a visual signal. The sensitivity and specificity of the methodology are based on bifunctional target labeling during the amplification step or subsequent hybridization that generates a bifunctional label. The invention may be used, for example, in the screening of amplicon detection for the purpose of more efficiently screening libraries. The invention is also useful to detect nucleic acid sequences indicative of a genetic defect or contagious disease when used with the appropriate primers, as well as detect the existence of nucleic acid amplification.
    Type: Grant
    Filed: June 17, 1996
    Date of Patent: November 23, 1999
    Assignee: Molecular Innovations, Inc.
    Inventor: John C. Gerdes